Reviews of Pediatric Studies Conducted Under BPCA and Pediatric Assessments Conducted Under PREA From 2012 – Present

Why It Matters

These reviews demonstrate the FDA’s commitment to ensuring pediatric safety and efficacy, influencing labeling, market access, and future drug development strategies. They provide a transparent benchmark for sponsors and clinicians assessing pediatric therapeutic options.

Key Takeaways

• 88 products studied under BPCA since 2012
• 544 products assessed under PREA in same period
• 83 products underwent both BPCA and PREA reviews
• FDA releases medical, pharmacology, statistical reviews publicly
• Data highlights extensive pediatric evaluation across drug classes

Pulse Analysis

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) form the regulatory backbone for pediatric drug evaluation in the United States. Since 2012, the FDA has released comprehensive reviews—medical, clinical pharmacology, and statistical—for hundreds of products, reflecting a systematic effort to address the historic gap in pediatric data. With 88 BPCA‑driven studies and 544 PREA assessments, the agency’s database underscores the scale of mandatory pediatric research and its role in shaping safe, age‑appropriate labeling.

A closer look at the dataset reveals diverse therapeutic areas, from antivirals like abacavir/lamivudine to biologics such as abatacept and adalimumab biosimilars. Many sponsors, including major innovators and generic manufacturers, have submitted overlapping reviews, resulting in 83 products evaluated under both statutes. This overlap often signals complex development pathways where a Written Request under BPCA complements mandatory PREA requirements, ensuring robust data packages that satisfy both voluntary incentives and statutory obligations.

For industry stakeholders, the publicly available reviews serve as a valuable reference point for future pediatric trial design, risk‑benefit assessments, and regulatory strategy. Clinicians benefit from clearer labeling and evidence‑based dosing guidance, while policymakers can gauge the effectiveness of current incentives. As pediatric pharmacology continues to evolve, the FDA’s transparent repository will likely drive more nuanced, condition‑specific studies, ultimately improving therapeutic outcomes for children across therapeutic classes.